Phaseline

Companies › Red de Terapia Celular

Red de Terapia Celular: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Gastroenterology, Immunology, Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mesenchymal stem cells (MSC)
Bone marrow-derived mesenchymal stem cells for immunomodulation in lupus nephritis
–Phase 2Lupus Nephritis; Chronic Pancreatitis; Diabetes Mellitus, Type 1Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05925036Mesenchymal stem cells (MSC)Phase 1Chronic PancreatitisGastroenterologyDec 2026
NCT04061746Mesenchymal stem cells (MSC)Phase 1Diabetes Mellitus, Type 1Metabolic and endocrineMay 2027
NCT03673748Mesenchymal stem cells (MSC)Phase 2Lupus NephritisImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biocomposites Estar Medical dba Medical Technologies Restem Xentria Wellizen Australia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.